{"id":23220,"date":"2023-04-20T12:15:14","date_gmt":"2023-04-20T10:15:14","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=23220"},"modified":"2023-04-20T12:19:08","modified_gmt":"2023-04-20T10:19:08","slug":"tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/","title":{"rendered":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients"},"content":{"rendered":"<p><strong>Tubulis <\/strong>and<strong> Bristol Myers Squibb<\/strong> (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).<\/p>\n<p>Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis\u2019 Tubutecan payloads in combination with Tubulis\u2019 proprietary P5 conjugation platform for the<br \/>\ndevelopment of a selected number of highly differentiated ADCs to treat solid tumors. P5 and Tubutecans facilitate the generation of ultra-stable ADCs that have the potential to actively reduce unwanted target-independent toxicities and are optimized for on-target delivery of potent topoisomerase-1 inhibitors.<\/p>\n<p>The terms of the agreement include an upfront payment of $22.75 million to Tubulis in addition to the potential for over $1 billion in development, regulatory, and commercial milestone payments plus royalty payments on resulting marketed products. Following antibody target selection by Bristol Myers Squibb, Tubulis will provide the company with its linker-payload to generate a uniquely matched ADC for each antibody. Bristol Myers Squibb will assume sole responsibility for development, manufacturing, and commercialization of the resulting ADC candidates.<\/p>\n<p>\u201c<em>This strategic agreement with Bristol Myers Squibb is an important validation of the potential of our approach in developing next-generation ADC-based therapeutics and our cutting-edge ADC <\/em><em>conjugation technologies that accommodate advanced ADC design to tackle tumors with high-unmet medical need<\/em>,\u201d said<strong> Dominik Schumacher, PhD, CEO and co-founder of Tubulis<\/strong>. \u201c<em>We are committed to transforming oncology treatment paradigms and to deliver better outcomes for cancer patients. Joining forces with BMS, a leading global oncology company, is a significant step towards achieving that goal.<\/em>\u201d<\/p>\n<p>\u201c<em>ADCs play a promising role in cancer therapy, and Tubulis\u2019 differentiated technologies offer opportunities to overcome current challenges in the development of safe and effective ADC<\/em><br \/>\n<em>therapeutic<\/em>s,\u201d <strong>said Emma Lees, PhD, Senior Vice President, Research and Early Development and Head, Mechanisms of Cancer Resistance Thematic Research Center at Bristol Myers Squibb<\/strong>. \u201c<em>With the P5 platform, we will be able to pair the right antibody with the right payload and thus provide potential for meaningful therapeutic benefits for patients with solid tumors. We are looking forward to a fruitful partnership with the Tubulis team.<\/em>\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs). Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis\u2019 Tubutecan payloads in combination with Tubulis\u2019 proprietary P5 conjugation platform for the development of a selected number&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-23220","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs). Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis\u2019 Tubutecan payloads in combination with Tubulis\u2019 proprietary P5 conjugation platform for the development of a selected number...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T10:15:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-20T10:19:08+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients\",\"datePublished\":\"2023-04-20T10:15:14+00:00\",\"dateModified\":\"2023-04-20T10:19:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/\"},\"wordCount\":364,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/\",\"name\":\"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2023-04-20T10:15:14+00:00\",\"dateModified\":\"2023-04-20T10:19:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/","og_locale":"fr_FR","og_type":"article","og_title":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients - ANDERA PARTNERS","og_description":"Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs). Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis\u2019 Tubutecan payloads in combination with Tubulis\u2019 proprietary P5 conjugation platform for the development of a selected number...","og_url":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2023-04-20T10:15:14+00:00","article_modified_time":"2023-04-20T10:19:08+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients","datePublished":"2023-04-20T10:15:14+00:00","dateModified":"2023-04-20T10:19:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/"},"wordCount":364,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/","url":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/","name":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2023-04-20T10:15:14+00:00","dateModified":"2023-04-20T10:19:08+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/23220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=23220"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/23220\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=23220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=23220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}